
Covetrus CVET
Quarterly report 2022-Q2
added 12-16-2023
Covetrus Income Statement 2011-2026 | CVET
Annual Income Statement Covetrus
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
2.48 B | 4.02 B | 1.32 B | 1.49 B | 1.49 B | - | - | - | - | - | - |
Shares |
137 M | 118 M | 107 M | 71 M | 71 M | - | - | - | - | - | - |
Historical Prices |
18.1 | 34.1 | 12.3 | - | - | - | - | - | - | - | - |
Net Income |
-54 M | -19 M | -980 M | 101 M | 64 M | 70.3 M | 60.3 M | - | - | - | - |
Revenue |
4.58 B | 4.34 B | 3.98 B | 3.78 B | 3.58 B | 3.35 B | 2.98 B | - | - | - | - |
Cost of Revenue |
3.72 B | 3.54 B | 3.23 B | 3.09 B | 2.93 B | - | - | - | - | - | - |
Gross Profit |
858 M | 798 M | 749 M | 684 M | 652 M | 620 M | 530 M | - | - | - | - |
Operating Income |
-23 M | -69 M | -997 M | 137 M | 135 M | - | - | - | - | - | - |
Interest Expense |
32 M | 46 M | 54 M | 3 M | 2 M | - | - | - | - | - | - |
EBITDA |
148 M | 98 M | -843 M | 201 M | 194 M | 187 M | 162 M | - | - | - | - |
Operating Expenses |
- | 867 M | 808 M | 538 M | 517 M | 489 M | 418 M | - | - | - | - |
General and Administrative Expenses |
881 M | 867 M | 808 M | 538 M | 517 M | 489 M | 418 M | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Covetrus
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | - | 140 M | 138 M | 138 M | 137 M | 137 M | 136 M | 136 M | 116 M | 112 M | 112 M | 112 M | 112 M | 112 M | 95 M | - | 71 M | 71 M | 71.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
- | - | -4 M | -2 M | - | -4 M | -31 M | -16 M | -4 M | -35 M | 54 M | -33 M | -37 M | -962 M | -10 M | -14 M | 33 M | 16 M | 29 M | 23 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
- | - | - | 1.15 B | - | 1.16 B | 1.19 B | 1.1 B | 1.12 B | 1.13 B | 1.03 B | 1.06 B | 1.01 B | 1.02 B | 1.01 B | 941 M | 903 M | 923 M | 1 B | 947 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | 923 M | - | 946 M | 969 M | 892 M | - | 929 M | 834 M | 863 M | - | 827 M | 816 M | 764 M | - | 757 M | 822 M | 771 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | 229 M | 225 M | - | 216 M | 220 M | 210 M | 206 M | 197 M | 192 M | 202 M | 188 M | 191 M | 193 M | 177 M | 159 M | 166 M | 183 M | 176 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
- | - | 4 M | 6 M | - | -4 M | -9 M | -3 M | -19 M | -27 M | -4 M | -20 M | -25 M | -958 M | -5 M | -9 M | 33 M | 34 M | 38 M | 32 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | 2 M | - | -2 M | 9 M | 9 M | - | 10 M | 14 M | 14 M | - | 16 M | 15 M | 12 M | - | - | 1 M | 1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
- | - | 45 M | 46 M | - | 38 M | 34 M | 40 M | -19 M | 14 M | 37 M | 20 M | -25 M | -917 M | 36 M | 21 M | 33 M | 50 M | 54 M | 48 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
- | - | - | 219 M | - | 220 M | 229 M | 213 M | - | 224 M | 196 M | 222 M | - | 210 M | 198 M | 186 M | - | 132 M | 139 M | 143 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Covetrus (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Accolade
ACCD
|
- | 0.29 % | $ 206 M | ||
|
Cerner Corporation
CERN
|
- | - | $ 27.9 B | ||
|
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | ||
|
Change Healthcare
CHNG
|
- | - | $ 9.03 B | ||
|
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | ||
|
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | ||
|
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | ||
|
iCAD
ICAD
|
- | - | $ 102 M | ||
|
Evolent Health
EVH
|
$ 2.78 | 10.76 % | $ 260 M | ||
|
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | ||
|
10x Genomics
TXG
|
$ 25.25 | 1.81 % | $ 2.96 B | ||
|
GoodRx Holdings
GDRX
|
$ 2.3 | 3.13 % | $ 887 M | ||
|
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | ||
|
Akerna Corp.
KERN
|
- | - | $ 161 M | ||
|
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | ||
|
OptimizeRx Corporation
OPRX
|
$ 6.29 | 3.97 % | $ 108 M | ||
|
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | ||
|
Health Catalyst
HCAT
|
$ 1.23 | 9.38 % | $ 86 M | ||
|
HealthEquity
HQY
|
$ 83.37 | 2.47 % | $ 7.18 B | ||
|
Premier
PINC
|
- | - | $ 2.33 B | ||
|
Schrödinger
SDGR
|
$ 12.4 | 4.11 % | $ 911 M | ||
|
Phreesia
PHR
|
$ 9.0 | 4.65 % | $ 538 M | ||
|
R1 RCM
RCM
|
- | - | $ 3.81 B | ||
|
Teladoc Health
TDOC
|
$ 5.51 | 5.06 % | $ 971 M | ||
|
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | ||
|
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | ||
|
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | ||
|
SCWorx Corp.
WORX
|
- | - | $ 7.71 M | ||
|
American Well Corporation
AMWL
|
$ 5.8 | 6.32 % | $ 93.1 M | ||
|
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | ||
|
HealthStream
HSTM
|
$ 20.7 | 1.77 % | $ 629 M | ||
|
Omnicell
OMCL
|
$ 36.92 | 1.64 % | $ 1.7 B | ||
|
Progyny
PGNY
|
$ 17.33 | 0.93 % | $ 1.49 B | ||
|
So-Young International
SY
|
$ 2.72 | -1.63 % | $ 216 M | ||
|
Veeva Systems
VEEV
|
$ 166.16 | 4.47 % | $ 27.2 B | ||
|
Zhongchao
ZCMD
|
$ 1.95 | -1.76 % | $ 6.67 M |